Treatment Approach for Young, Fit Patients with Extensive, High Disease Burden Mantle Cell Lymphoma

Recommended Induction Regimens

The European Society for Medical Oncology recommends young, fit patients with extensive and high disease burden MCL to receive intensive cytarabine-containing immunochemotherapy followed by autologous stem cell transplantation (ASCT), with rituximab maintenance thereafter 1, 2
The National Comprehensive Cancer Network recommends intensive induction with one of the following cytarabine-containing regimens: Nordic regimen, Alternating R-CHOP/R-DHAP, or R-HyperCVAD/MA, which demonstrated event-free survival exceeding 60% at 5 years and 5-year overall survival of 75% 3
The American Society of Clinical Oncology recommends R-HyperCVAD/MA, which consists of rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine 1, 4, 5

For patients ≤65 years, 15-year failure-free survival plateaus at 30%, with median OS not reached and median time to treatment failure of 5.9 years 4
The National Comprehensive Cancer Network analysis demonstrated superior PFS outcomes with R-HyperCVAD or rituximab-containing regimens followed by ASCT compared to R-CHOP alone in younger patients (<65 years) 7, 4, 5

The European Society for Medical Oncology recommends ASCT consolidation in first remission as mandatory for young, fit patients, as it demonstrates higher response and survival rates independently of rituximab addition 1, 2
Total body irradiation (TBI) before ASCT provides benefit only in partial response patients, not those achieving complete response 1

The American Society of Clinical Oncology recommends rituximab maintenance significantly improves both progression-free survival and overall survival and must be administered after induction therapy 1, 2, 6

The National Comprehensive Cancer Network recommends high-dose cytarabine is essential—avoid using HD-AraC alone without combination chemotherapy, as it achieves insufficient response rates 1, 2
The European Society for Medical Oncology recommends considering the interaction between cytarabine and purine analogs when addressing dose and toxicity concerns 3
The American Society of Clinical Oncology recommends patients with TP53 mutation should be strongly considered for clinical trial enrollment, as conventional treatment yields poor outcomes 3, 2
The National Comprehensive Cancer Network recommends pleomorphic or blastoid variants require the same intensive approaches outlined above; do not undertreat based on histologic variant 2, 6

The European Society for Medical Oncology recommends not using antibody monotherapy alone (rituximab or radioimmunotherapy)—it achieves only moderate response rates 1, 2
The American Society of Clinical Oncology recommends not using R-CHOP alone in young, fit patients with high disease burden—this is inadequate therapy 7, 4, 5
The National Comprehensive Cancer Network recommends not omitting or reducing cytarabine dose—this is the most critical component of induction therapy 3
The European Society for Medical Oncology recommends not skipping ASCT consolidation in eligible patients—this significantly impacts long-term outcomes 1, 2